Prosecution Insights
Last updated: April 19, 2026

Genmont Biotech Incorporation

2 pending office actions

Portfolio Summary

2
Total Pending OAs
1
Final Rejections
1
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18791967 USE OF NUCLEOTIDE OF LACTOBACILLUS FERMENTUM GM-090 FOR PREPARING PHARMACEUTICAL COMPOSITION FOR REGULATING IMMUNITY DAVIS, RUTH A 1699 Non-Final OA Aug 01, 2024
17862766 COMPOSITION WITH LACTOBACILLUS PARACASEI AND A METHOD TO TREAT NASOPHARYNGEAL CARCINOMA THROUGH PYROPTOSIS OR CELL CYCLE ARREST DURYEE, ALEXANDER MARSH 1657 Final Rejection Jul 12, 2022

Managing Genmont Biotech Incorporation's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month